Sector News

Pfizer to shut 55-year-old Mumbai manufacturing plant

July 15, 2015
Life sciences
Pfizer Ltd, the Indian unit of global pharmaceutical major Pfizer Inc., has decided to shut its manufacturing facility at Thane, near Mumbai, with effect from 16 September, the company said on Wednesday.
 
There has been no production activity at the plant since 2013, and the closure will not impact the supply of any of its medicines, according to company.
 
The decision to close the site is based on an assessment of its long-term viability and its ability to achieve the needed production, the statement said.
 
This Thane plant was commissioned in the 1960s. Pfizer had offered voluntary retirement scheme (VRS) to the workmen at the plant last year, which was taken up by as many as 132 of the 212 workmen, the company said.
 
The remaining 80 workmen continue to receive full wages, despite plant inactivity. As part of the closure process, the company will honour its obligations towards requisite compensation, as mandated by law, for the remaining workmen, it said.
 
Source: Live Mint

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach